Published in final edited form as:

J Med Chem. 2012 October 25; 55(20): 8943–8947. doi:10.1021/jm3006959.

Vitamin B₁₂ Derivatives as Activators of Soluble Guanylyl Cyclase

Keith ó Proinsias^a, Daniel T. Gryko^{a,b}, Yoshio Hisaeda^{c,*}, Emil Martin^{d,*}, Jonathan L. Sessler^{b,*}, and Dorota Gryko^{a,b,*}

^aInstitute of Organic Chemistry PAS, Kasprzaka 44/52, 01 – 224 Warsaw, Poland ^bDepartment of Chemistry & Biochemistry, 1 University Station-A5300, The University of Texas, Austin, Texas, 78712 ^cDepartment of Chemistry and Biochemistry, Graduate School of Engineering, Kyushu University, Motooka, Nishi-ku, Fukuoka 819-0395 ^dDepartment of Internal Medicine, Division of Cardiology, University of Texas Health Science Center in Houston, 1941 East Road, The University of Texas, Houston, Texas 77054

Abstract

Various newly prepared and previously known vitamin B₁₂ derivatives have been studied as potential soluble guanylyl cyclase (sGC) activators. All compounds tested were found to activate the sGC enzyme, although to differing extents. The best results were obtained with the derivatives synthesized from *c*-lactone and possessing aliphatic amides in the *c*- and *d*-positions.

Keywords

Vitamin B₁₂; cobalamin; cobinamide; guanylyl cyclase

INTRODUCTION

Nitric oxide signaling is one of the fundamental pathways in mammalian physiology. It plays an important role in cardiovascular homeostasis, platelet function, angiogenesis and neurotransmission. One of the key mediators of NO signaling is soluble guanylyl cyclase (sGC), a heme protein with high affinity for NO. The binding of NO to the heme moiety present in sGC serves to enhance by two or three orders of magnitude its capacity to convert guanosine triphosphate (GTP) into a second messenger, cyclic guanosine monophosphate (cGMP). The resulting increase in intracellular cGMP concentration further triggers cGMP-dependent cellular effects that ultimately produce the characteristic physiological responses associated with NO signaling. For instance, sGC activation in smooth muscle cells leads to muscle relaxation and contributes to vasodilatation.^{1,2} Likewise, NO-dependent activation of sGC inhibits adhesion of leukocyte and platelets to vascular walls, aggregation of platelets; it also decreases proliferation and migration of smooth muscles cells.³ In this respect,

*Corresponding Author: Prof. Dorota Gryko: Phone: +48 22 343 2051; Fax: +48 22 632 6681; dorota.gryko@icho.edu.pl; or Prof. Jonathan L. Sessler: Phone: 512 471-5009; Fax: 512 471-7550; sessler@mail.texas.edu or Emil Martin: Phone: 713-4862441; Fax: 713-4860450; emil.martin@uth.tmc.edu or Prof. Yoshio Hisaeda: Phone 092-802-2826; Fax: 092-802-2827; yhisatcm@mail.cstm.kyushu-u.ac.jp.

Author Contributions

The manuscript was written through contributions of all authors.

Complete experimental procedures and characterization data and ¹H and ¹³C NMR spectra for all new compounds. Experimental procedure for enzyme purification and assay of sGC activity *in vitro*. Supporting is available free of charge via the Internet at <http://pubs.acs.org>.

activation and maintenance of sGC function is beneficial for maintaining normal vascular plasticity, preventing atherosclerosis,⁴ thrombosis⁵ and stroke;⁶ it also helps promote lung development in premature infants.⁷ On the other hand, aberrations in NO-dependent pathways result in decreased vasodilatory function and contribute significantly to the development of cardiovascular, renal, pulmonary and other pathologies associated with the diminished function of the endothelium.⁸

Not surprisingly, sGC has long been a therapeutic target and its function is currently regulated pharmacologically by various NO releasing organic nitrites, such as glyceryl trinitrate, isosorbide dinitrate, isosorbide-5-mononitrate. These agents are routinely used to treat disorders such as angina pectoris, myocardial infarction, congestive heart failure and hypertension.⁹ Direct inhalation of NO gas is also used to manage persistent pulmonary hypertension in newborns.¹⁰ Although the NO-based activation of sGC currently represents an art-accepted approach to producing useful clinical outcomes, a number of problems are associated with this generalized strategy. For instance, the effectiveness of inhaled NO is patient specific – some patients do not respond to the treatment, while a few even develop adverse reactions.¹¹ The use of nitro-vasodilators is also problematic, since patients often develop tolerance to nitrovasodilators.¹² Moreover, under inflammatory conditions, NO interacts with reactive oxygen species (ROS), leading to the formation of peroxynitrite (ONOO⁻), which damages DNA, proteins and lipids.¹³ In these instances, NO-based targeting of sGC may produce more harm than benefit. In a quest to overcome these problems, a number of compounds, which activate sGC through NO-independent mechanisms have been described in the last decade.^{14,15} As a general rule, these reported sGC regulators are thought to target the heme-containing regulatory domain of sGC. However, Martin and co-workers have recently reported that sGC could be activated by dicyanocobinamide **1** (Chart 1) via the catalytic domain.^{16,17} They found that this vitamin B₁₂ derivative not only activates the enzyme in vitro, but upregulates its function in intact cells and isolated aortic rings as well. Subsequently, it was reported that dicyanocobinamide derivatives, with seven peripheral hydrophilic or hydrophobic substituents, are also effective as sGC activating agents.¹⁸ Other derivatives, such as those containing a different number of amide substituents, were not included in these prior reports.

The present study has thus been carried out with view to generalizing these previous results and obtaining basic structure-activity information. Towards this end, we have prepared several new cobalamin derivatives bearing various substituents at the periphery of the macrocycle and tested their sGC activation ability and those of related known compounds in vitro. As detailed below, some of the derivatives examined in this study displayed an sGC activating potential that was 240% greater than that of **1**.

To explore the effect that changes in structure would have on sGC activation, various acid, ester, and monamide derivatives of dicyanocobinamide, either known or newly prepared for this study, were selected for testing. In certain instances one or both of the cyano ligands present in **1** were either replaced by water or removed altogether by reduction to the corresponding Co(II) species. For the sake of organization, the compounds are discussed according to the type of derivative prepared and the nature of the synthetic methodology employed to obtain the specific compound in question. Because the goal of the study was to obtain general insights, not all members of a given structural class were subject to biological testing.

RESULTS AND DISCUSSION

Chemistry

As a first step in our structure-function analysis, the hydrophilic and hydrophobic cobalamin derivatives **2** – **5** were prepared and studied. This series was designed to give insights into the effect, if any, on activity that would come from increasing or decreasing the water solubility of the basic macrocyclic structure. To obtain a more water soluble derivative, vitamin B₁₂ was transformed into the corresponding heptaacid **2**. This was done following a literature procedure.¹⁹

In contrast, the presence of -CO₂Me groups in these positions was expected to increase hydrophobicity, thus allowing increased penetration into a lipid membrane. To test this proposition, vitamin B₁₂ was subject to hydrolysis followed by esterification with methanol. This produced the hydrophobic ester **3**,²⁰ a species that was subsequently transformed into the mono-aqua complex **4** in accord with a literature procedure.²¹ Compound **3** was also reduced to the corresponding Co(II) complex, **5**. Having this latter complex in hand would, it was thought, provide insights into the role the redox state of the metal might play in regulating sGC activity.²¹

A second set of analogues was also studied. This series of compounds consisted of esterified vitamin B₁₂ derivatives that retain the amide functionality present in **1**, while varying the amine that makes up the amide. Here, we sought to test the possibility that simply changing the amide moiety on a cobalamin would affect the activity of the resulting vitamin B₁₂ derivative. Thus, a set of mono- and diamides possessing various terminal groups, including aliphatic, hydroxyl, methoxy, azide and propargyl, as well as more complex amides, were prepared and examined as potential sGC activators. The compounds in question are shown in Schemes 1 and 2. They were chosen as targets since they embody the presumably favorable structural features of amide **1** and hexaesters **3**–**5**. Their synthesis is detailed below.

The initial set of monoamide derivatives was obtained starting from the α -acid **6**. Compound **6** was prepared from vitamin B₁₂ via the lactone route.²² It was transformed into its monoaquo species by washing with HClO₄,^{23,24} followed by coupling with various amines, using DEPC as a coupling reagent. This afforded amides **7** – **10** in good yields (Scheme 1).^{25,26}

The amide bond could also be introduced via the direct ring opening of the α -lactone **11** with amines (Scheme 2).²⁷ Since many of the species produced in this way cannot be accessed via the direct coupling method of Scheme 1, this ring opening approach was considered to be a useful complement to more classic amide-forming strategies. Compound **15** was synthesized using a previously published method, which incorporates the use of spirolactone **14**.

While the large number of derivatives prepared in this way precluded the biological analysis of every compound (cf. SI for a full list of compounds and their characterization data), it did allow selected systems, representative of general compound type, to be chosen for study. The results of these studies are detailed later on in this report.

All new compounds prepared in the context of this study were characterized by ¹H NMR spectroscopy, elemental analysis, and ESI MS (see Supporting Information).

Biological Results

Once the corrinoids described above were in hand, their effect on sGC activity was tested. Towards this end, purified enzyme was first incubated with different amounts of the cobinamide of interest. Then, the cGMP-forming activity of sGC was determined using the assay described in the Experimental section. While some cobinamides were ineffective, most of the tested compounds displayed some degree of dose dependent sGC activation. Representative dose-response curves are shown in Figure 1. Following this assay-based approach, the half maximal effective concentration (EC_{50}) for each of the activating cobinamides was determined (Table 1). Consistent with our previous report, dicyanocobinamide was found to activate sGC in a dose-dependent manner with a maximal 8-fold activation and an estimated $34 \mu M$ EC_{50} being observed. These same experiments also revealed that changes in the cobinamide structure had a profound effect on the extent of sGC activation. Some derivatives (e.g., compounds **2**, **7**, **9** and **10** in Table 1) displayed sGC activation, which was lower than the standard against which they were benchmarked, namely compound **1** dicyanocobinamide. A few others induced activation at a level similar to compound **1** (e.g., compounds **3**, **5** and **12g** in Table 1). Several of these latter agents were, however, characterized by an improved effective concentration. This makes them of interest. Finally, as shown in Figure 1 and Table 1, some cobinamide derivatives (**13d**, **14** and **15**) produced a higher level of activation than compound **1**. Based on the combined total of the data, we conclude that cobalamin diamide derivatives, particularly those bearing branched and long-chain alkyl substituents, are promising candidates for sGC activation.

A more detailed analysis of the sGC-activating cobinamides revealed that the derivatives of this study may be divided into two groups. One set displays a typical one phase dose-dependent activation of sGC (Fig. 1A). As shown in Table 1, many of these compounds had an improved affinity towards sGC as demonstrated by decreased EC_{50} (Table 1). Another group of compounds displayed a bell-shaped dose-dependent activation curve (Fig. 1B). Such biphasic behavior is consistent with the existence of a secondary cobinamide binding site with lower affinity. To the extent this supposition is correct, this second site exerts an inhibitory effect on sGC. Both the EC_{50} for the activating site and the IC_{50} for the putative inhibitory site are shown in Table 1. As a rule, the diamides generally displayed enhanced inhibitory activity as compared to the analogous monoamides.

Previous studies served to demonstrate that dicyanocobinamide activates sGC through a mechanism different from other sGC activators.¹⁶ Unlike nitric oxide or any of the NO-independent activators previously described, dicyanocobinamide activates sGC by directly targeting the catalytic domain of the enzyme.¹⁶

The catalytic domain of sGC is composed of the C-terminal regions of the α and β subunits, both of which are required for catalysis. These subunits have a 60% homology in the catalytic region, which leads to the prediction that the catalytic domain has a pseudosymmetric structure.²⁸ Such a presumed pseudosymmetric structure may account for the existence of two cobinamide-binding sites with different affinities. The existence of a two-site arrangement is reminiscent of the substrate and pseudosubstrate organization predicted for GTP analogs.²⁹ Nevertheless, further study will be required before the exact localization of the cobinamide-binding sites can be determined.

CONCLUSIONS

Existing NO-independent activators were shown to be effective in a variety of experimental animal models and to have therapeutic promise for a range of cardiovascular and non-cardiovascular disorders. These latter disorders includes arterial and pulmonary hypertension, peripheral arterial disease, heart failure, renal fibrosis, erectile dysfunction,

peripheral arterial occlusive disease, atherosclerosis, restenosis, thrombosis and others.^{14,15} Previous investigations served to demonstrate that dicyanocobinamide synergistically enhances the effects of all classes of NO-independent sGC regulators, leading us to suggest that corrin species may be used in combination with these previously known agents so as to enhance their therapeutic potential. However, to be effective, relatively high concentrations of dicyanocobinamide are required. This is likely to limit its pharmacological use. The compounds presented in this report either display improved effective concentrations and/or enhanced sGC activating potential. Future investigations will test if this augmented effectiveness *in vitro* translates into improved sGC activating potency *in vivo*.

EXPERIMENTAL SECTION

Chemistry

General and Materials—All solvents and chemicals used in the syntheses were of reagent grade and were used without further purification. Full description of ¹H and ¹³C NMR data for all new compounds are in the SI. Tested compounds were greater than 95% chemical purity as measured by HPLC analysis. Vitamin B₁₂ was purchased from Aldrich.

Preparation of compound 7: *c*-Acid (**6**)^{4,5} (15 mg, 0.014 mmol) was dissolved in dimethylformamide (DMF; 1 mL) and cooled to 0 °C using an ice-bath under a nitrogen atmosphere. DEPC (9 μL, 0.06 mmol) was added to the solution, followed by Gly-OMe (4.0 mg, 0.04 mmol) and triethylamine (8 μL, 0.12 mmol). The reaction mixture was stirred for 6 h at 0 °C, and then 17 h at room temperature under a nitrogen atmosphere. The mixture was then diluted with dichloromethane (DCM) and washed with water. The organic layer was separated and dried over anhydrous Na₂SO₄, and evaporated to dryness. The product was purified using DCVC, 2.5% EtOH in DCM. After recrystallization from hexanes/AcOEt, compound **7** was isolated as a purple solid (14 mg, 86%). R_f 0.50, 5% EtOH in dichloromethane (DCM). LRMS ESI (*m/z*) calcd. for C₅₅H₇₆CoN₆O₁₅ [M-CN]⁺ 1120.1; found 1120.1. UV/Vis CH₂Cl₂, λ_{max}, ε (L·mol⁻¹·cm⁻¹): 588 (1.05×10⁴), 5.49 (8.62×10³), 422 (2.72×10³), 371 (2.78×10⁴), 317 (9.52×10³), 279 (1.09×10⁴).

Preparation of compound 8: Following the procedure for compound **7**, compound **8** was isolated as a purple solid (51 mg, 54%). R_f 0.50, 5% EtOH in DCM. LRMS ESI (*m/z*) calcd. for C₅₆H₇₈CoN₆O₁₆ [M-CN]⁺ 1149.5; found 1149.9. UV/Vis CH₂Cl₂, λ_{max}, ε (L·mol⁻¹·cm⁻¹): 589 (9.791×10³), 550 (7.64×10³), 424 (2.55×10³), 371 (2.65×10⁴), 317 (8.99×10³), 279 (1.00×10⁴).

Preparation of compound 9: Following the procedure for compound **7**, compound **9** was isolated as a purple solid (190 mg, 45%). MALDI-TOF-MS (*m/z*): [M-2CN]⁺, 1112. UV/Vis CH₂Cl₂: 278, 312, 370, 421, 510(sh), 547 and 587.

Preparation of compound 10: Following the procedure for compound **7**, compound **10** was isolated as a purple solid (74 mg, 48%). MALDI-TOF-MS (*m/z*): [M-CN]⁺, 1344. UV/Vis CH₂Cl₂: 371, 421, 510(sh), 547 and 587.

Preparation of compound 12a: Following a reported procedure,²⁷ compound **12a** was isolated as a purple solid (14 mg, 87%). R_f 0.37, 5% EtOH in DCM. HRMS ESI (*m/z*) calcd. for C₅₇H₈₂CoN₆O₁₅ [M-CN]⁺ 1149.5164; found 1149.5177. UV/Vis CH₂Cl₂, λ_{max}, ε (L·mol⁻¹·cm⁻¹): 281 (9.50 × 10³), 319 (9.45 × 10³), 372 (2.68 × 10⁴), 426 (2.68 × 10³), 553 (8.29 × 10³), 591 (1.01 × 10⁴).

Preparation of compound 12b: Following a reported procedure,²⁷ compound **12b** as a purple solid (12 mg, 75%). R_f 0.36, 5% EtOH in DCM. HRMS ESI (m/z) calcd. for $C_{56}H_{80}CoN_6O_{15}$ $[M-CN]^+$ 1135.5028; found 1135.5008. UV/Vis CH_2Cl_2 , λ_{max} , ϵ ($L \cdot mol^{-1} \cdot cm^{-1}$): 281 (9.73×10^3), 319 (9.57×10^3), 372 (2.77×10^4), 426 (2.93×10^3), 554 (8.50×10^3), 593 (1.06×10^4).

Preparation of compound 13b: Following a reported procedure,²⁷ compound **13b** was isolated as a purple solid (9 mg, 52%). R_f 0.13, 5% EtOH in DCM. HRMS ESI (m/z) calcd. for $C_{59}H_{87}CoN_7O_{15}$ $[M-CN]^+$ 1192.5572; found 1192.5586. UV/Vis CH_2Cl_2 , λ_{max} , ϵ ($L \cdot mol^{-1} \cdot cm^{-1}$): 281 (9.61×10^3), 319 (9.46×10^3), 372 (2.65×10^4), 425 (3.15×10^3), 553 (8.40×10^3), 591 (9.82×10^3).

Preparation of compound 12f: Following a reported procedure,²⁷ compound **12f** was isolated as a purple solid (22 mg, 72%). R_f 0.32, 5% EtOH in DCM. HRMS ESI (m/z) calcd. for $C_{54}H_{76}CoN_6O_{15}$ $[M-CN]^+$ 1188.5389; found 1188.5386. UV/Vis CH_2Cl_2 , λ_{max} , ϵ ($L \cdot mol^{-1} \cdot cm^{-1}$): 281 (8.85×10^3), 319 (9.11×10^3), 372 (2.26×10^4), 427.5 (3.12×10^3), 556 (7.15×10^3), 592 (8.62×10^3).

Preparation of compound 12h: Following a reported procedure,²⁷ compound **12h** was isolated as a purple solid (33 mg, 45%). R_f 0.48, 5% EtOH in DCM. HRMS ESI (m/z) calcd. for $C_{60}H_{87}CoN_9O_{17}$ $[M-CN]^+$ 1264.5512; found 1264.5546. UV/Vis CH_2Cl_2 , λ_{max} , ϵ ($L \cdot mol^{-1} \cdot cm^{-1}$): 281 (9.42×10^3), 319 (9.09×10^3), 372 (2.57×10^4), 426 (2.92×10^3), 554 (7.84×10^3), 593 (9.96×10^3).

Biology

Purification of recombinant human sGC enzyme and determination of its activity—Recombinant human sGC enzyme was purified as described previously from Sf9 cells infected with baculoviruses expressing $\alpha 1$ and $\beta 1$ sGC subunits.³⁰ Only preparations with NO-induced activity $>5 \mu moles/min/mg$ were used for the present studies. To evaluate the effect of synthesized cobinamides on sGC, 0.1 μg sGC was preincubated for 10 minutes at 25°C with the indicated concentration of the compound; this was followed by testing in the $\alpha[^{32}P]GTP \rightarrow [^{32}P] cGMP$ conversion assay as described previously.¹⁷

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding Sources

These studies were supported in part by NIH grants 5R01HL088128 and 3R01HL088128-02S1 (E.M.), AHA Grant-in-Aid 09GRNT2060182 (E.M.), by the European Regional Found within TEAM program, grant TEAM/2009-3/4 (D.G. and K.6P) and by the Texas Institute for Diagnostic and Drug Development under a grant from the Robert A. Welch Foundation (RAWF) (grant no. H-F-0032) (J.L.S., D.G. and D.T.G.). J.L.S. thanks the RAWF for additional support (grant no. F-1018).

ABBREVIATIONS

sGC	Soluble guanylyl cyclase
DIC	diisopropylcarbodiimide
DEPC	diethyl cyanophosphate

References

1. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. *Biosci Rep.* 1999; 19:51–71. [PubMed: 10888468]
2. Gruetter CA, Barry BK, McNamara DB, Grutter DY, Kadowitz PJ, Ignarro L. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. *J Cyclic Nucleotide Res.* 1979; 5:211–224. [PubMed: 39089]
3. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. *New Engl J Med.* 2006; 355:2003–2011. [PubMed: 17093251]
4. Griffith TM, Lewis MJ, Newby AC, Henderson AH. Endothelium-derived relaxing factor. *J Am Coll Cardiol.* 1988; 12:797–806. [PubMed: 3042836]
5. Just M, Martorana PA, Nitz RE. Inhibition of platelet functions by molsidomine in animals. *Pathol Biol (Paris).* 1987; 35:226–228. [PubMed: 3550643]
6. Tulis DA. Salutary properties of YC-1 in the cardiovascular and hematological systems. *Curr Med Chem Cardiovasc Hematol Agents.* 2004; 2:343–359. [PubMed: 15320784]
7. Roberts JD, Fineman JR, Morin FC, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, Heymann MA, Zapol WM, Thusu KG, Zellers TM, Wylam ME, Zaslavsky A. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. *Lancet.* 1992; 340:818–819. [PubMed: 1357245]
8. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. *Circ Res.* 2000; 87:840–844. [PubMed: 11073878]
9. Abrams J. Beneficial actions of nitrates in cardiovascular disease. *Am J Cardiol.* 1996; 77:31C–37C. [PubMed: 8540453]
10. Roberts JD, Zapol, Zapol WM. Inhaled nitric oxide. *Semin Perinatol.* 2000; 24:55–58. [PubMed: 10709861]
11. Kinsella JP, Abman SH. Inhaled nitric oxide in the premature newborn. *J Pediatr.* 2007; 151:10–15. [PubMed: 17586183]
12. Torfgard KE, Ahlner J. Mechanisms of action of nitrates. *Cardiovasc Drugs Ther.* 1994; 8:701–717. [PubMed: 7873467]
13. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. *Nat Clin Pract Cardiovasc Med.* 2008; 5:338–349. [PubMed: 18461048]
14. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. *Handb Exp Pharmacol.* 2009; 191:277–308. [PubMed: 19089334]
15. Schmidt HHHW, Schmidt PM, Stasch JP. NO- and Haem-Independent Soluble Guanylate Cyclase Activators. *Handb Exp Pharmacol.* 2009; 191:309–339. [PubMed: 19089335]
16. Martin E, Sharina IG, Liang YY, Doursout MF. Corrin-mediated activation of NO receptor and its cardiovascular consequences. *Circulation.* 2009; 120:S1072.
17. Sharina I, Sobolevsky M, Doursout MF, Gryko D, Martin E. Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain. *J Pharmacol Exp Ther.* 2012; 340:723–723. [PubMed: 22171090]
18. Proinsias K, Giedyk M, Sharina IG, Martin E, Gryko D. *ACS Med Chem Lett.* 2012; 3:476–479.
19. Izumi S, Shimakoshi H, Abe M, Hisaeda Y. Photo-Induced Ring-Expansion Reactions Mediated by B₁₂-TiO₂ Hybrid Catalyst. *Dalton Trans.* 2010; 39:3302–3307. [PubMed: 20449460]
20. Werthemann L, Keese R, Eschenmoser A. unpublished results. ; see Werthemann L. Dissertation, ETH Zürich (Nr 4097). Juris Druck and Verlag Zürich 1968
21. Murakami Y, Hisaeda Y, Kajihara A. Hydrophobic Vitamin B₁₂. I. Preparation and Axial Ligation Behavior of Hydrophobic Vitamin B₁₂. *Bull Chem Soc Jpn.* 1983; 56:3642–3646.
22. Pfammatter MJ, Dabre T, Keese R. Synthesis of vitamin-B₁₂ derivatives with peripheral tris(oxyethylene)chains. *Helv Chim Acta.* 1998; 81:1105–1116.
23. Murakami Y, Hisaeda Y, Ohno T, Kohnno H, Nishioka T. Hydrophobic vitamin B₁₂. Part 12. Preparation, characterization and enantioselective alkylation of strapped hydrophobic vitamin B₁₂. *J Chem Soc, Perkin Trans.* 1995; 2:1175–1183.

24. Shimakoshi H, Tokunaga M, Kuroiwa K, Kimizuka N, Hisaeda Y. Preparation and electrochemical behaviour of hydrophobic vitamin B₁₂ covalently immobilized onto platinum electrode. *Chem Commun.* 2004;50–51.
25. Sun F, Darbre T, Keese R. Synthesis of vitamin B₁₂ derivatives incorporating peripheral cytosine and N-acetylcytosine. *Tetrahedron.* 1999; 55:9777–9786.
26. Yamada S, Kasai Y, Shioiri T. Diethylphosphoryl cyanide. A new reagent for the synthesis of amides. *Tetrahedron Lett.* 1973; 14:1595–1973.
27. Proinsias K, Sessler JL, Kurco S, Gryko D. New hydrophobic vitamin B₁₂ derivatives *via* ring-opening reactions of α -lactone. *Org Lett.* 2010; 12:4674–4677. [PubMed: 20866038]
28. Sunahara RK, Beuve A, Tesmer JJG, Sprang SR, Garbers DL, Gilman AG. Exchange of Substrate and Inhibitor Specificities between Adenylyl and Guanylyl Cyclases. *J Biol Chem.* 1998; 273:16332–16338. [PubMed: 9632695]
29. Yazawa S, Tsuchiya H, Hori H, Makino R. Functional Characterization of Two Nucleotide-binding Sites in Soluble Guanylate Cyclase. *J Biol Chem.* 2006; 28:21763–21770. [PubMed: 16754683]
30. Martin E, Berka V, Tsai AL, Murad F. Soluble Guanylyl Cyclase: The Nitric Oxide Receptor. *Methods Enzymol.* 2005; 396PE:478–492. [PubMed: 16291255]

$R^1 = \text{NH}_2$	$R^2 = \text{CH}_2\text{CH}(\text{OH})\text{CH}_3$	$X = \text{CN}$	1
$R^1 = \text{OH}$	$R^2 = \text{OH}$	$X = \text{CN}, \text{H}_2\text{O}$	2
$R^1 = \text{OMe}$	$R^2 = \text{OMe}$	$X = \text{CN}$	3
$R^1 = \text{OMe}$	$R^2 = \text{OMe}$	$X = \text{CN}, \text{H}_2\text{O}$	4
$R^1 = \text{OMe}$	$R^2 = \text{OMe}$		5

Figure 1.
Hydrophilic and hydrophobic vitamin B₁₂ derivatives.

Figure 2. Stimulation of sGC activity by cobinamide derivatives

Purified human sGC (0.5 μg) was preincubated for 5 minutes with the indicated concentration of the cobinamide derivative in question and then tested for cGMP-forming activity using the [^{32}P]GTP assay as described in the Experimental Section. Data are shown as mean $\pm$ SD from two independent experiments performed in triplicate. Dose response curves display features consistent with either a monophasic (A) or a biphasic (B) regulation of sGC activity. The symbols are means $\pm$ SD ($n=6$), while the solid lines are nonlinear regression curve fits obtained using the sigmoidal dose-response (A) or two-site competition (B) algorithms of the GraphPad Prism 5 software (GraphPad Software, LaJolla, CA, USA). See text for discussion.

Scheme 1.
Coupling of *c*-acid 6 with amines.^a
^a(i) DEPC, R-NH₂, Et₃N, DMF

Derivative	R ¹	R ²
12a	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ OH	OMe
12b	-CH ₂ CH ₂ CH ₂ OCH ₃	OMe
12c ²⁷	-CH ₂ CH ₂ CH ₂ CH ₃	OMe
12d ²⁷	-CH ₂ (CH ₂) ₆ CH ₃	OMe
12e ²⁷	-CH ₂ (CH ₃) ₂	OMe
12f	-CH ₂ (CH ₂) ₄ CH ₂ N ₃	OMe
12g ²⁷	-CH ₂ C≡CH	OMe
12h	-(CH ₂ CH ₂ O) ₃ CH ₂ CH ₂ N ₃	OMe
13a	-C ₂ H ₄ OC ₂ H ₄ OH	-C ₂ H ₄ OC ₂ H ₄ OH
13b ²⁷	-CH ₂ CH ₂ CH ₂ OCH ₃	-CH ₂ CH ₂ CH ₂ OCH ₃
13c	-CH ₂ CH ₂ CH ₂ CH ₃	-CH ₂ CH ₂ CH ₂ CH ₃
13d ²⁷	-CH(CH ₃) ₂	-CH(CH ₃) ₂
15 ²⁷	-CH ₂ CH ₂ OH	-C ₂ H ₄ OC ₂ H ₄ OH

Scheme 2.
Synthesis of mono and di-amides from *c*-lactone.

Table 1Vitamin B₁₂ derivatives with sGC-stimulating properties

Entry	Derivative	EC50 [μ M] ^b	IC50 [μ M] ^b	Activity ratio relative to compound 1
1	1	34.2	n/a ^a	1
2	2	20.5	547	0.48
3	3	9.3	n/a	0.92
4	4	14.1	39.8	1.34
5	5	4.5	12.6	0.96
6	7	17.4	n/a	0.71
7	8	20.5	547.6	0.74
8	9	5.3	n/a	0.53
9	10	10.1	n/a	0.42
10	12a	25.1	158.5	0.77
11	12b	12.6	316	0.84
12	12c	16.4	204.9	0.91
13	12d	3.8	n/a	0.57
14	12e	25	251	0.8
15	12f	34.7	316.2	0.88
16	12g	11.9	n/a	1.13
17	12h	12.7	n/a	0.71
18	13a	5.6	n/a	0.28
19	13d	101	n/a	2.5
20	14	9	n/a	1.31
21	15	7.5	n/a	1.37

^a not applicable;^b EC50 and IC50 were calculated via nonlinear regression using the GraphPad Prism 5.